iPSCs & Single Cell Isolation – Clinical Manufacturing Workflow Considerations

For cell therapy manufacturing, an important aspect of an investigational new drug (IND) application is demonstrating that the generated cell line is clonally derived while fulfilling GMP regulations.

In this webinar, we will explore key considerations for the early stage of clinical manufacturing including single cell deposition methods, the importance of monoclonality assurance, consistency in the workflow, and the reduction of project timelines.

Key learning objectives

• Recognize the key considerations for clinical manufacturing under GMP regulations
• Understand the importance of monoclonality assurance for IND submission
• Learn about the new GMP-compliant technology for improved single cell deposition

Discover the best approach to track clones during their journey through the manufacturing process.